Cardiocast

New LDL-lowering drug under FDA review

Publish date: March 14, 2019

 

This week in MDedge Cardiocast: A novel drug lowers LDL in on top of maximums statins, invasive cardiology is a top money maker for hospitals, a meta-analysis parses the heart and kidney benefits of new diabetes drugs, and the AHA warns that heart-harming toxins may hurt hookah smokers.
Amazon Alexa
Apple Podcasts
Google Podcasts
TuneIn

Recommended Reading

Statin adherence lower in women, minorities
MDedge Internal Medicine
Hormone therapy in transgender individuals may up risk of CV events
MDedge Internal Medicine
Who is least adherent to statins, and more
MDedge Internal Medicine
AHA: Consider obesity as CVD risk factor in children
MDedge Internal Medicine
FDA accepts supplemental New Drug Application to expand lorcaserin label
MDedge Internal Medicine
FDA approves label extension for dapagliflozin
MDedge Internal Medicine
AHA drills into CV risk factors in children
MDedge Internal Medicine
Semaglutide plus SGLT2 inhibitors improves glycemic control in type 2 diabetes
MDedge Internal Medicine
Newer antihyperglycemic drugs have distinctive CV, kidney benefits
MDedge Internal Medicine
Bempedoic acid safely dropped LDL, now seeks FDA approval
MDedge Internal Medicine